Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1611-1620 Newer>

The Motley Fool December 16, 2004 Rich Duprey	A Big Beat for CardioDynamics The medical device maker receives FDA clearance for new heart monitoring technology. Will management be able to push BioZ across the chasm, or will investors continue to suffer palpitations with each passing quarter?
The Motley Fool December 15, 2004 Brian Gorman	Korea's Biotech Bet Korea's new facility could stimulate biotech research in Asia and lower costs for biotech companies.
The Motley Fool December 15, 2004 Brian Gorman	Wyeth Keeps Producing The drug maker's difficulties are evident, but its productivity may make it worth an investor's second look.
The Motley Fool December 14, 2004 Charly Travers	A Stagnant Drug Stock A drug launch is not driving share price increases for Indevus.
The Motley Fool December 14, 2004 Brian Gorman	Bristol-Myers' Smart Moves Although problems still hang over the company, Bristol-Myers is paving the way for recovery. In the meantime investors will surely be jittery.
The Motley Fool December 14, 2004 Charly Travers	Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor.
The Motley Fool December 13, 2004 Charly Travers	PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success.
The Motley Fool December 13, 2004 W.D. Crotty	Tenet: A Real Soap Opera The acute care hospital operator Tenet Healthcare sees bad news for quarters to come. With today's news, the stock is down almost 10% to under $11.
The Motley Fool December 13, 2004 Brian Gorman	Which Medications Are Your Best Bets? Consumer Reports' effort to rate drugs offers a marketing lesson to pharmaceutical companies.
Bio-IT World November 19, 2004 Lentini & Bent	Intellectual Property: Patents and Genomic Medicine Patents, so critical to encouraging investment in developing new technologies, threaten to become a legal and economic minefield that could prevent effective commercial exploitation of genomics.
<Older 1611-1620 Newer> Return to current articles.